KRYS Krystal Biotech, Inc.
XNAS
306.50
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
KRYS
$306.50
—
What changed
Recent filings, trades and movesKey stats
$306.50
- 52-Week Range
- $198.02 – $382.54
- YTD
- +24.13%
- IV Rank (30D)
- 18.8
- Straddle Price
- $31.50
- P/C Vol Ratio
- 1.08
- Market Cap
- $9.0B
- Open
- $302.60
- Day Range
- $300.86 – $307.48
- Volume
- 196,377
- Prev Close
- $303.06
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.84% |
| Beta vs SPY | 0.89 |
| Cost of Equity (CAPM) | 9.29% (VRP-adj) |
| WACC | 9.37% |
| Volatility Risk Premium | -0.1pp (IV − HV30) |
| Effective Tax Rate | 13.0% |
| Rev. Growth (YoY, DCF input) | +18.9% |
| DCF Horizon | 15 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $0.3B |
| Return on Equity (TTM) | 15.7% |
| Book / Price | 15.4% |
| Gross Margin (TTM) | 94.3% |
| FCF Margin (TTM) | 66.0% |
| Debt / Equity | 0.00 |
| Quality Score | 6/6 — compounder (15y DCF) |
| Market-Implied Growth | +11.7% (reverse-DCF on current price) |
| SMA 50 | $331.52 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $316.32 |
| Bollinger Width / SMA20 | 13.3% (drives anchor stability) |
| Net Debt | $-0.5B |
| Market Cap | $9B |
Peers used for multiples: GH, LGND, LLY, MRNA, NTRA, TWST, UTHR, VRTX
60-Day Conviction
36%
20-Day Fair Value
≈ by Dec 9, 2026
$301.48
α +0.0%
rank 15%
conviction
2%
40-Day Fair Value
≈ by Jan 7, 2027
$304.70
α +1.1%
rank 20%
conviction
40%
60-Day Fair Value
≈ by Feb 5, 2027
$305.26
α +1.3%
rank 24%
conviction
36%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $500.00 | 20% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $318.25 | 9% | median 39.3× · 4 peers |
| Peer EV/EBITDA | $251.57 | 9% | median 28.4× · 4 peers |
| Peer P/B | $698.75 | 2% | median 15.0× · 7 peers |
| Peer P/S | $263.64 | 6% | median 15.7× · 8 peers |
| Market Anchor (SMA50) | $331.52 | 34% | stability 84% (BB-width) |
| Options Expected (B-L 30d) | $302.80 | 20% | 27 strikes · skew +0.25 |
As of 2026-11-10 · updated
Related
About
- Industry (SIC)
- BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
- Exchange
- XNAS
- Market Cap
- $9.0B
- Employees
- 295
- List Date
- 2017-09-20
- CIK
- 0001711279
- Last Earnings
- Nov 2 before open · −11.0% vs ±10.2% expected
- Next Earnings
- ~Feb 16, 2027 (estimated)
- Headquarters
- Pittsburgh, PA
- Homepage
- https://www.krystalbio.com
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United Stat…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 17.30% | -18.18% | 4.91% | -10.97% | 2.07% | 13.09% | 1.37% |
| Feb | 14.45% | 7.64% | 0.24% | 42.95% | 12.71% | -2.35% | 12.61% |
| Mar | -9.85% | 3.73% | -3.54% | 6.02% | 4.93% | -0.19% | 0.18% |
| Apr | 3.55% | -14.45% | 4.54% | -13.03% | -2.69% | 1.29% | -3.46% |
| May | -15.27% | -7.49% | 36.73% | 0.24% | -23.98% | 16.16% | 1.06% |
| Jun | 5.02% | 12.93% | 0.48% | 11.80% | 9.65% | 24.68% | 10.76% |
| Jul | -18.57% | 7.57% | 10.45% | 14.37% | 10.69% | -8.37% | 2.69% |
| Aug | 0.09% | 0.49% | -4.41% | -1.84% | -5.91% | 14.97% | 0.57% |
| Sep | -15.05% | -1.62% | -8.12% | -2.54% | 18.48% | -8.60% | -2.91% |
| Oct | -7.05% | 10.34% | 4.75% | -4.93% | 9.97% | 2.15% | 2.54% |
| Nov | 57.79% | 1.08% | -12.64% | 11.92% | 10.18% | 1.85%* | 11.70% |
| Dec | 0.39% | 2.88% | 16.75% | -19.62% | 14.61% | -- | 3.00% |
| Total | 13.68% | -0.37% | 50.99% | 23.06% | 67.78% | 61.98% | 36.19% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $315.58
SMA 50: $330.46
SMA 200: $309.26
Current: $306.50
EMA 12: $309.77
EMA 26: $317.15
MACD: -7.3797 | Signal: -0.7942
BEARISH
ADX (14): 19.07
RANGE
+DI: 17.14
−DI: 25.93
Momentum Oscillators
RSI (14): 43.46
NEUTRAL
Stoch %K: 43.10
Stoch %D: 42.07
Williams %R: -51.01
Volume & Volatility
BB Upper: $336.89
BB Lower: $294.28
NEUTRAL
OBV: 9,061,100
Vol SMA 20: 333,664
Vol ROC: -7.72%
ATR: $12.30
True Range: $6.62
HV 20: 52.8%
HV 30: 46.6%
HV 60: 39.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-12T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before KRYS’s Nov 2 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report: KRYS
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Bullish momentum signals from MACD and Bollinger Bands
- Neutral RSI reading, indicating no strong buying or selling pressure
- Low volatility compared to market, with beta of 0.81
Recent News Sentiment Impact: Positive news headlines, including the upcoming presentation at the Cantor Global Healthcare Conference, contribute to a neutral bias.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Uptrend
- Medium-term (1-3 months): Range-bound
- Long-term (3-12 months): Bullish
Support/Resistance Levels: Key price levels include:
- SMA 20 ($346.82) as a support level
- Upper Bollinger Band ($374.75) as a resistance level
- Middle Bollinger Band ($346.82) as a potential support level
Momentum Signals:
- RSI (14): 54.87 (neutral)
- MACD signal line crossover: Bullish momentum
- Bollinger Bands position: Neutral, with no clear trend direction
Volume Analysis: Moderate volume flow, with no clear trend direction.
News & Sentiment Analysis
Recent Headlines Summary: Positive news headlines focus on upcoming presentations and earnings reports.
Sentiment Assessment: Positive sentiment from recent headlines (4/5) is tempered by a neutral RSI reading.
Catalyst Identification: Upcoming presentation at the Cantor Global Healthcare Conference (September 3, 2026).
Market Narrative: Technical signals are mixed, with bullish momentum from MACD and Bollinger Bands offset by neutral RSI and range-bound price action. News sentiment is positive, which could support further gains.
Risk & Volatility Assessment
Beta Interpretation: Moderate risk relative to market (beta of 0.81).
Volatility Regime: Low volatility compared to market, with average true range (ATR) of $12.40 and historical volatility of HV20 31.5%.
Options Market Signals:
- IV Rank: 3.3% (Low)
- Current IV: 40.7%
- Expected Move: $39.90 (42 DTE)
Market Context & Positioning
Sector Performance: Krystal Biotech's performance is stronger than its sector, with a relative strength index of 0.26.
Institutional Activity: Moderate institutional interest, with 292 calls and 185 puts open.
Correlation Analysis: Strong positive correlation (R-squared) between KRYS and market indices.
Relative Valuation: Position within trading range, with no clear trend direction.
Key Levels & Action Items
Critical Price Levels:
- SMA 20 ($346.82) as a support level
- Upper Bollinger Band ($374.75) as a resistance level
- Middle Bollinger Band ($346.82) as a potential support level
Breakout/Breakdown Levels: No clear breakout or breakdown levels are apparent.
Time-Sensitive Catalysts: Upcoming presentation at the Cantor Global Healthcare Conference (September 3, 2026).
Risk Management: Monitor RSI and Bollinger Bands for signs of overbought or oversold conditions. Set stop-loss levels around SMA 20 ($346.82) to manage risk.
By analyzing these technical indicators, news sentiment, and market context, we conclude that KRYS is in a neutral position with moderate risk. The stock's performance is stronger than its sector, and institutional interest is moderate. Further gains are possible, but caution is advised due to the mixed signals from RSI and Bollinger Bands.
Generated
News
All KRYS news →
VYJUVEK revenue surged 30% YoY to $127.3 million amid $400 million buyback authorization.
Earnings History
12 of 18 under expected move
Avg Expected Move
12.53%
Avg Actual Move
8.31%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-11-08 | Pre-Market | 20.46% | 4.33% | 0.21x | Within |
| 2022-02-28 | Pre-Market | 11.49% | 1.68% | 0.15x | Within |
| 2022-08-08 | Pre-Market | 4.18% | 0.38% | 0.09x | Within |
| 2022-11-07 | Pre-Market | 11.54% | 6.61% | 0.57x | Within |
| 2023-02-27 | Pre-Market | 10.96% | 0.41% | 0.04x | Within |
| 2023-05-08 | Pre-Market | 18.44% | 4.05% | 0.22x | Within |
| 2023-08-07 | Pre-Market | 8.90% | 12.63% | 1.42x | Exceeded |
| 2023-11-06 | Pre-Market | 12.48% | 15.05% | 1.21x | Exceeded |
| 2024-02-26 | Pre-Market | 17.78% | 41.02% | 2.31x | Exceeded |
| 2024-05-06 | Pre-Market | 13.25% | 2.58% | 0.19x | Within |
| 2024-08-05 | Pre-Market | 15.50% | 5.85% | 0.38x | Within |
| 2024-11-04 | Pre-Market | 14.12% | 3.14% | 0.22x | Within |
| 2025-05-06 | Pre-Market | 10.75% | 14.06% | 1.31x | Exceeded |
| 2025-08-04 | Pre-Market | 10.83% | 14.04% | 1.30x | Exceeded |
| 2025-11-03 | Pre-Market | 13.01% | 0.17% | 0.01x | Within |
| 2026-02-17 | Pre-Market | 9.59% | 4.22% | 0.44x | Within |
| 2026-08-03 | Pre-Market | 11.98% | 8.37% | 0.70x | Within |
| 2026-11-02 | Pre-Market | 10.25% | 10.95% | 1.07x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
KRYS Options Activity & IV Rank
KRYS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 39.5%
7-DTE IV: 40.4%
Expected Move: $31.50
7-DTE Move: $16.65
Days to Exp: 38 (2026-12-18)
Options Flow · All expiries
Call Volume: 853
Put Volume: 922
P/C Volume: 1.081
NEUTRAL
Call OI: 3,229
Put OI: 3,237
P/C OI: 1.002
Total OI: 6,466
ATM Options Pricing
ATM Call: $14.40
ATM Put: $17.10
Call %: 4.7%
Put %: 5.6%
Chain Summary
Chain Volume: 1,775
Chain OI: 6,466
Last Updated: 11/10/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 49th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
49%
vs own history
GEX tilt
+0.23
OI-weighted, today
Vanna tilt
+0.22
δ-sensitivity to IV
Charm tilt
-0.41
δ-decay vs time
Charm tilt -0.41: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 33 ATM contracts, 3k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Nov 10 · No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)16.7LowNov 10
IV Rank (30 DTE)18.8LowNov 10
Straddle Price (30 DTE)$31.50Nov 10
Beta Analysis
Risk Metrics
Beta: 0.7434
Alpha: 41.58%
Correlation: 0.2582
R-Squared: 6.7%
Stock Volatility: 39.4%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own KRYS
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $22.2M | #657 of 3138 | +521.7% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $20.3M | #203 of 997 | +17.5% | 13F | |
| Citadel Hedge fund Ken Griffin | $1.0M | #3681 of 6285 | -0.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $81K | #3102 of 4729 | -6.1% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
KRYS Institutional Ownership (13F)
Filings for 2026-06-30 · 195 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 30,588,250 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
13 filers$96.77M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Caption Management, LLC | $28.99M | 29.96% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $21.15M | 21.85% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $13.57M | 14.02% | 2026-06-30 |
| 4 | D. E. Shaw & Co., Inc. Custodian | $9.92M | 10.25% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $9.03M | 9.33% | 2026-06-30 |
| 6 | Citigroup Inc. Custodian | $3.99M | 4.12% | 2026-09-30 |
| 7 | GROUP ONE TRADING LLC Custodian | $2.82M | 2.92% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $2.49M | 2.58% | 2026-09-30 |
| 9 | Walleye Capital LLC | $1.56M | 1.61% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $1.20M | 1.24% | 2026-09-30 |
| 11 | Two Sigma Investments, LP Custodian | $929.17K | 0.96% | 2026-06-30 |
| 12 | UBS Group AG Custodian | $892.01K | 0.92% | 2026-06-30 |
| 13 | Squarepoint Ops LLC | $223.00K | 0.23% | 2026-06-30 |
13 filers$83.97M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Nantahala Capital Management, LLC | $31.59M | 37.62% | 2026-06-30 |
| 2 | Caption Management, LLC | $19.55M | 23.28% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $18.96M | 22.57% | 2026-06-30 |
| 4 | UBS Group AG Custodian | $4.20M | 5.00% | 2026-06-30 |
| 5 | Citigroup Inc. Custodian | $3.99M | 4.75% | 2026-09-30 |
| 6 | IMC-Chicago, LLC Custodian | $1.46M | 1.74% | 2026-09-30 |
| 7 | Citadel Advisors LLC Custodian | $1.41M | 1.68% | 2026-06-30 |
| 8 | Jane Street Group, LLC Custodian | $1.19M | 1.42% | 2026-06-30 |
| 9 | Two Sigma Investments, LP Custodian | $483.17K | 0.58% | 2026-06-30 |
| 10 | Simplex Trading, LLC Custodian | $432.33K | 0.51% | 2026-09-30 |
| 11 | Walleye Capital LLC | $371.67K | 0.44% | 2026-06-30 |
| 12 | D. E. Shaw & Co., Inc. Custodian | $297.34K | 0.35% | 2026-06-30 |
| 13 | GROUP ONE TRADING LLC Custodian | $37.17K | 0.04% | 2026-06-30 |
KRYS Insider Trading (Form 4)
Latest: 2026-09-16Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-16 | Julian S Gangolli | Director | Grant (A) | +1,658 RSU | — | EDGAR | |
| 2026-09-16 | Everett Rand Sutherland | Director | Grant (A) | +1,658 opt | — | EDGAR | |
| 2026-09-16 | Christopher Mason | Director | Grant (A) | +1,658 RSU | — | EDGAR | |
| 2026-09-16 | Daniel Janney | Director | Grant (A) | +1,658 RSU | — | EDGAR | |
| 2026-09-16 | Catherine Mazzacco | Director | Grant (A) | +1,658 RSU | — | EDGAR | |
| 2026-09-16 | Dino A Rossi | Director | Grant (A) | +1,658 opt | — | EDGAR | |
| 2026-09-04 | Suma Krishnan | President, R&D | Sell (S) | −25,000 | $359.32 | -$8.98M | EDGAR |
| 2026-09-04 | Krish S Krishnan | President and CEO | Sell (S) | −25,000 | $359.32 | -$8.98M | EDGAR |
| 2026-08-14 | Dino A Rossi | Director | Mixed Sell −25,000 · Gift −3,691 |
−28,691 | $329.12 | -$8.23M | EDGAR |
| 2026-06-26 | John Charles Thomas | EVP, General Counsel | Mixed Sell −1,000 · Exer +1,000 |
— | $263.26 | -$168.0K | EDGAR |
| 2026-06-05 | Suma Krishnan | President, R&D | Sell (S) | −25,000 | $308.11 | -$7.70M | EDGAR |
| 2026-06-05 | Krish S Krishnan | President and CEO | Sell (S) | −25,000 | $308.12 | -$7.70M | EDGAR |
| 2026-05-27 | John Charles Thomas | EVP, General Counsel | Sell (S) | −642 | $302.03 | -$193.9K | EDGAR |
| 2026-03-06 | Suma Krishnan | President, R&D | Sell (S) | −25,000 | $263.21 | -$6.58M | EDGAR |
| 2026-03-06 | Krish S Krishnan | President and CEO | Sell (S) | −25,000 | $263.17 | -$6.58M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
KRYS Insider Holdings
6 insiders · @ $306.50
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Krish S Krishnan | President and CEO | 1,400,726 | $429.32M | -$133.66M | 37 | 2026-09-04 |
| 2 | Suma Krishnan | President, R&D | 1,356,274 | $415.70M | -$133.58M | 38 | 2026-09-04 |
| 3 | Daniel Janney | Director | 74,036 | $22.69M | -$42.01M | 17 | 2026-09-16 |
| 4 | Dino A Rossi | Director | 53,135 | $16.29M | -$16.51M | 13 | 2026-09-16 |
| 5 | Kathryn Romano | Chief Accounting Officer | 23,356 | $7.16M | -$12.67M | 12 | 2026-03-03 |
| 6 | John Charles Thomas | EVP, General Counsel | 1,000 | $306.5K | -$541.2K | 2 | 2026-06-26 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
KRYS Board & Officers
As of SEC filings through Sep 16, 2026Directors 8
- Daniel Janney · since Sep 19, 2017
- Dino A Rossi · since Sep 19, 2017
- Krish S Krishnan · since Sep 19, 2017
- Suma Krishnan · since Sep 19, 2017
- Julian S Gangolli · since Mar 1, 2019
- Christopher Mason · since Jan 4, 2021
- Everett Rand Sutherland · since Jan 18, 2022
- Catherine Mazzacco · since Mar 6, 2023
Officers 5
- Krish S Krishnan · President and CEO · since Sep 19, 2017
- Suma Krishnan · President, R&D · listed since Mar 2022
- Kathryn Romano · Chief Accounting Officer · since Jan 20, 2020
- John Charles Thomas · EVP, General Counsel · since Mar 1, 2026
- Laurent Louis Jean Goux · EVP, Head of International · since Mar 1, 2026
10% owners 2
- Krish S Krishnan · since Sep 19, 2017
- Suma Krishnan · since Sep 19, 2017
Changes in the last 10 years (26)
| Mar 1, 2026 | Laurent Louis Jean Goux became EVP, Head of International |
| Mar 1, 2026 | John Charles Thomas became EVP, General Counsel |
| Aug 2, 2023 | The company announced the departure of Andrew C. Orth as Chief Commercial Officer in an SEC filing |
| Mar 6, 2023 | Catherine Mazzacco became a director |
| Mar 1, 2022 | Suma Krishnan listed as President, R&D (previously Chief Operating Officer) in SEC filings |
| Jan 31, 2022 | Jing L. Marantz first listed as Chief Business Officer in an SEC filing |
| Jan 18, 2022 | Everett Rand Sutherland became a director |
| Jan 12, 2022 | The company announced the departure of Jing L. Marantz from the board in an SEC filing |
| May 1, 2021 | Andrew C. Orth became Chief Commercial Officer |
| Jan 4, 2021 | Jing L. Marantz became a director |
| Jan 4, 2021 | Christopher Mason became a director |
| Jan 20, 2020 | Kathryn Romano became Chief Accounting Officer |
| Jan 20, 2020 | Jennifer Chien became Chief Commercial Officer |
| Mar 1, 2019 | Julian S Gangolli became a director |
| Mar 8, 2018 | Antony A Riley became Chief Financial Officer |
| Sep 19, 2017 | Sun Pharma (Netherlands) B.V. became a 10% owner |
| Sep 19, 2017 | Suma Krishnan became a director |
| Sep 19, 2017 | Suma Krishnan became a 10% owner |
| Sep 19, 2017 | Suma Krishnan became Chief Operating Officer |
| Sep 19, 2017 | R Douglas Norby became a director |
| Sep 19, 2017 | Krish S Krishnan became a director |
| Sep 19, 2017 | Krish S Krishnan became a 10% owner |
| Sep 19, 2017 | Krish S Krishnan became President and CEO |
| Sep 19, 2017 | Kirti Ganorkar became a director |
| Sep 19, 2017 | Dino A Rossi became a director |
| Sep 19, 2017 | Daniel Janney became a director |
Not reported recently (6)
- Kirti Ganorkar · Last reported as a director in an SEC filing dated May 23, 2023
- Jing L. Marantz · Last reported as Chief Business Officer in an SEC filing dated Jan 31, 2022
- Jennifer Chien · Last reported as Chief Commercial Officer in an SEC filing dated Feb 4, 2020
- Antony A Riley · Last reported as Chief Financial Officer in an SEC filing dated Nov 21, 2019
- R Douglas Norby · Last reported as a director in an SEC filing dated Jun 4, 2018
- Sun Pharma (Netherlands) B.V. · Last reported as a 10% owner in an SEC filing dated Sep 25, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
KRYS Proposed Insider Sales (Form 144)
Latest: 2026-09-04
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
3 filings
· $26.9M notice value
· 3 unique filers
· 67% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-04 | SUMA KRISHNAN | Director, Officer, 10% Stockholder | 25,000 | $9.29M | 2026-09-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-04 | KRISH KRISHNAN | Director, Officer, 10% Stockholder | 25,000 | $9.29M | 2026-09-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-14 | Dino A. Rossi | Director | 25,000 | $8.31M | 2026-08-14 | Goldman Sachs & Co. LLC | — | EDGAR |
| 2026-06-25 | Thomas John Charles | Officer | 1,000 | $347.3K | 2026-06-25 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-06-04 | SUMA KRISHNAN | Director, Officer, 10% Stockholder | 25,000 | $7.55M | 2026-06-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-04 | KRISH KRISHNAN | Director, Officer, 10% Stockholder | 25,000 | $7.55M | 2026-06-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-05-26 | Thomas John Charles | Officer | 642 | $193.9K | 2026-05-26 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-03-04 | SUMA KRISHNAN | Director, Officer, 10% Stockholder | 25,000 | $6.59M | 2026-03-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-04 | KRISH KRISHNAN | Director, Officer, 10% Stockholder | 25,000 | $6.59M | 2026-03-04 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-03-02 | ROMANO KATHRYN | Officer | 750 | $200.7K | 2026-03-02 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-02
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
138 ETFs hold KRYS
25 shown · $1.97B total exposure · 0.25% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJH iShares Core S&P Mid-Cap ETF | iShares (BlackRock) | 0.24% | $290.0M | $125.2B | 2026-11-06 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $282.1M | — | 2026-09-30 |
| 3 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.27% | $203.5M | $77.9B | 2026-11-06 |
| 4 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.11% | $199.3M | — | 2026-09-30 |
| 5 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.29% | $132.5M | $10.3B | 2026-11-06 |
| 6 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.25% | $111.1M | — | 2026-09-30 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.11% | $99.7M | — | 2026-09-30 |
| 8 | XMMO Invesco S&P MidCap Momentum ETF | Invesco | 1.30% | $80.2M | — | 2026-11-08 |
| 9 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.54% | $74.3M | $14.2B | 2026-11-06 |
| 10 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.19% | $64.7M | — | 2026-11-06 |
| 11 | MDY State Street® SPDR® S&P MIDCAP 400® ETF Trust | SPDR (State Street) | 0.24% | $60.6M | $25.5B | 2026-11-06 |
| 12 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 0.54% | $58.9M | $11.2B | 2026-11-06 |
| 13 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.29% | $50.5M | — | 2026-09-30 |
| 14 | IJK iShares S&P Mid-Cap 400 Growth ETF | iShares (BlackRock) | 0.48% | $48.9M | $10.5B | 2026-11-06 |
| 15 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.20% | $44.8M | — | 2026-08-31 |
| 16 | SPMD State Street® SPDR® Portfolio S&P 400™ Mid Cap ETF | SPDR (State Street) | 0.24% | $44.0M | $18.4B | 2026-11-06 |
| 17 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.03% | $27.1M | — | 2026-11-06 |
| 18 | VHT Vanguard Health Care ETF | Vanguard | 0.10% | $21.0M | — | 2026-09-30 |
| 19 | IVOO Vanguard S&P Mid-Cap 400 ETF | Vanguard | 0.26% | $14.8M | — | 2026-09-30 |
| 20 | MDYG State Street® SPDR® S&P 400™ Mid Cap Growth ETF | SPDR (State Street) | 0.48% | $13.2M | $2.7B | 2026-11-06 |
| 21 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $10.5M | $95.6B | 2026-11-06 |
| 22 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.57% | $9.5M | — | 2026-09-30 |
| 23 | PSC Principal U.S. Small-Cap ETF | Nport | 0.40% | $9.4M | — | 2026-06-30 |
| 24 | IVOG Vanguard S&P Mid-Cap 400 Growth ETF | Vanguard | 0.50% | $9.2M | — | 2026-09-30 |
| 25 | JSMD Janus Henderson Small/Mid Cap Growth Alpha ETF | Janus | 0.88% | $8.9M | $1.0B | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
41.64
TTM Diluted EPS
$7.36
TTM Revenue
$470.02M
TTM Net Income
$225.17M
TTM Op. Cash Flow
$323.93M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $127.34M | $63.07M | $2.05 | $91.25M |
| Q2 '26 | 2026-06-30 | $119.22M | $54.77M | $1.79 | $74.79M |
| Q1 '26 | 2026-03-31 | $116.36M | $55.93M | $1.83 | $80.38M |
| Q4 '25 | 2025-12-31 | $107.11M | $51.40M | $1.70 | $77.51M |
| Q3 '25 | 2025-09-30 | $97.80M | $79.36M | $2.66 | $39.66M |
| Q2 '25 | 2025-06-30 | $96.04M | $38.33M | $1.29 | $52.73M |
| Q1 '25 | 2025-03-31 | $88.18M | $35.73M | $1.20 | $30.97M |
| Q4 '24 | 2024-12-31 | $91.14M | $45.48M | $1.53 | $52.84M |
| Q3 '24 | 2024-09-30 | $83.84M | $27.18M | $0.91 | $58.86M |
| Q2 '24 | 2024-06-30 | $70.28M | $15.57M | $0.53 | $-4.17M |
| Q1 '24 | 2024-03-31 | $45.25M | $932.00K | $0.03 | $15.89M |
| Q4 '23 | 2023-12-31 | $42.14M | $8.69M | $0.31 | $-7.23M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-02
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
41.64
P/B
6.82
P/S
21.04
EV/EBITDA
43.42
EV/Sales
20.07
ROE
17.8%
ROA
16.1%
Div Yield
0.00%
FCF Yield
2.94%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$9.27B
as of 2026-11-10
KRYS vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.26T | 46.5 | +45.5% | +32.6% | 27 |
| VRTX Vertex Pharmaceuticals Inc | $139.7B | 35.3 | +10.5% | +21.2% | 60 |
| MRNA Moderna, Inc. Common Stock | $108.8B | — | −27.6% | +712.8% | 47 |
| NTRA Natera, Inc. Common Stock | $46.5B | — | +36.6% | +36.3% | 40 |
| UTHR United Therapeutics Corp | $24.8B | 22.2 | +1.9% | +18.5% | 22 |
| GH Guardant Health, Inc. Common Stock | $21.5B | — | +42.7% | +52.7% | 24 |
| KRYS Krystal Biotech, Inc. Common Stock | $9.0B | 41.6 | +26.0% | +24.1% | 19 |
| TWST Twist Bioscience Corporation Common Stoc | $9.0B | — | +17.8% | +307.9% | 82 |
| LGND Ligand Pharmaceuticals Inc. | $6.3B | 142.2 | +1.0% | +65.3% | 34 |
| Peer median | $35.6B | 40.9 | +14.2% | +44.5% | 37 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.94M
SI % of Float
12.85%
Days to Cover
10.33
Short Vol Ratio
76.8%
Free Float
22.84M
Float %
77.2%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-08-24